Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sevim Bavbek"'
Publikováno v:
World Allergy Organization Journal, Vol 16, Iss 10, Pp 100822- (2023)
Externí odkaz:
https://doaj.org/article/bdfecd5d293d418db7020dde8400c650
Publikováno v:
World Allergy Organization Journal, Vol 16, Iss 3, Pp 100761- (2023)
Background: Anaphylaxis is a very dynamic issue with its incidence and trigger profile changing over the years. We aimed to compile the characteristics of anaphylaxis cases diagnosed in our clinic prospectively and to make a comparison between diagno
Externí odkaz:
https://doaj.org/article/50998acdbf474b1289cfb4cfc7ca1332
Autor:
Begum Gorgulu Akin, MD, Merve Erkoc, MD, Elif Tugce Korkmaz, MD, Betul Ozdel Ozturk, MD, Sevgi Colak, MD, Funda Seher Ozalp Ates, MD, Sevim Bavbek, MD
Publikováno v:
World Allergy Organization Journal, Vol 15, Iss 1, Pp 100619- (2022)
Background: All platin-based chemotherapeutics can cause hypersensitivity reactions (HSRs). With rapid drug desensitization (RDD), few patients experience breakthrough reactions (BTR) during desensitization. However, data about risk factors for BTRs
Externí odkaz:
https://doaj.org/article/b761c8d7d5174a6b98f6bf905b8de0de
Autor:
Zeynep Celebi Sozener, Begum Gorgulu, Dilsad Mungan, Betul Ayse Sin, Zeynep Misirligil, Omur Aydin, Sevim Bavbek
Publikováno v:
World Allergy Organization Journal, Vol 11, Iss 1, Pp 1-11 (2018)
Abstract Background Data are limited regarding the effectiveness of omalizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Our aim was to evaluate the clinical and functional effectiveness of omalizumab in patients with EGP
Externí odkaz:
https://doaj.org/article/6f0f92ecd2b44b32b4ebcaba327930bc
Autor:
Betül Ayşe Sin, Zeynep Misirligil, Dilşad Mungan, Zeynep Çelebi Sözener, Begüm Görgülü, Sevim Bavbek, Ömür Aydın
Publikováno v:
World Allergy Organization Journal, Vol 11, Iss 1, Pp 1-11 (2018)
The World Allergy Organization Journal
The World Allergy Organization Journal
Background Data are limited regarding the effectiveness of omalizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Our aim was to evaluate the clinical and functional effectiveness of omalizumab in patients with EGPA in long